Literature DB >> 29666806

The frontline of esophageal cancer treatment: questions to be asked and answered.

Cheng-Che Tu1, Po-Kuei Hsu2.   

Abstract

Achieving a good treatment for esophageal cancer is a great challenge. For early stage cancer, endoscopic treatment is considered the first line and a possible curative therapy. Chemotherapy, radiotherapy, and surgery are all used for the treatment of locally advanced esophageal cancer, administered either alone or combined. Some combinations have proven to be feasible, effective, and superior, such as neoadjuvant chemoradiation (CRT) plus surgery in the Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study (CROSS) trial. However, other strategies such as perioperative chemotherapy or definitive chemoradiation also have demonstrated substantial effectiveness. The current article addresses the following questions: (I) how can a choice between different multi-modality treatments be made; (II) is there enough evidence to compare the merits of the different strategies; and (III) is there any new evidence to improve the current practice. Moreover, in this article, existing evidence for treatment strategies for locally advanced esophageal cancer have been reviewed.

Entities:  

Keywords:  Chemoradiotherapy; chemotherapy; esophageal cancer; esophagectomy; radiotherapy; treatment strategy

Year:  2018        PMID: 29666806      PMCID: PMC5890033          DOI: 10.21037/atm.2017.10.31

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  55 in total

1.  Neoadjuvant chemoradiotherapy could improve survival outcomes for esophageal carcinoma: a meta-analysis.

Authors:  Dong-Bin Wang; Xun Zhang; Hong-Li Han; Yi-Jun Xu; Da-Qiang Sun; Zhen-Liang Shi
Journal:  Dig Dis Sci       Date:  2012-06-14       Impact factor: 3.199

2.  Effects of neoadjuvant radiochemotherapy on pathological staging and prognosis for locally advanced esophageal squamous cell carcinoma.

Authors:  X-F Cao; X-T He; L Ji; J Xiao; J Lv
Journal:  Dis Esophagus       Date:  2009       Impact factor: 3.429

3.  Patterns of recurrence after oesophagectomy and postoperative chemoradiotherapy versus surgery alone for oesophageal squamous cell carcinoma.

Authors:  P-K Hsu; H-S Chen; C-S Huang; C-C Liu; C-C Hsieh; H-S Hsu; Y-C Wu; S-C Wu
Journal:  Br J Surg       Date:  2016-11-15       Impact factor: 6.939

Review 4.  Preoperative chemotherapy for resectable thoracic esophageal cancer.

Authors:  Biniam Kidane; Shaun Coughlin; Kelly Vogt; Richard Malthaner
Journal:  Cochrane Database Syst Rev       Date:  2015-05-19

Review 5.  Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis.

Authors:  F Fiorica; D Di Bona; F Schepis; A Licata; L Shahied; A Venturi; A M Falchi; A Craxì; C Cammà
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

6.  Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.

Authors:  David P Kelsen; Katryn A Winter; Leonard L Gunderson; Joanne Mortimer; Norman C Estes; Daniel G Haller; Jaffer A Ajani; Walter Kocha; Bruce D Minsky; Jack A Roth; Christopher G Willett
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544

7.  A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma.

Authors:  J-L Lee; S I Park; S-B Kim; H-Y Jung; G H Lee; J-H Kim; H-Y Song; K-J Cho; W-K Kim; J-S Lee; S-H Kim; Y-I Min
Journal:  Ann Oncol       Date:  2004-06       Impact factor: 32.976

Review 8.  Magnification endoscopy in esophageal squamous cell carcinoma: a review of the intrapapillary capillary loop classification.

Authors:  Haruhiro Inoue; Makoto Kaga; Haruo Ikeda; Chiaki Sato; Hiroki Sato; Hitomi Minami; Esperanza Grace Santi; Bu'Hussain Hayee; Nikolas Eleftheriadis
Journal:  Ann Gastroenterol       Date:  2015 Jan-Mar

Review 9.  Concurrent neoadjuvant chemoradiotherapy could improve survival outcomes for patients with esophageal cancer: a meta-analysis based on random clinical trials.

Authors:  Baoxing Liu; Yacong Bo; Kunlun Wang; Yang Liu; Xiance Tang; Yan Zhao; Erjiang Zhao; Ling Yuan
Journal:  Oncotarget       Date:  2017-03-21

10.  Neoadjuvant Chemoradiotherapy Improving Survival Outcomes for Esophageal Carcinoma: An Updated Meta-analysis.

Authors:  Dong-Bin Wang; Zhong-Yi Sun; Li-Min Deng; De-Qing Zhu; Hong-Gang Xia; Peng-Zhi Zhu
Journal:  Chin Med J (Engl)       Date:  2016-12-20       Impact factor: 2.628

View more
  10 in total

1.  The mutation profiles of cell-free DNA in patients with oesophageal squamous cell carcinoma who were responsive and non-responsive to neoadjuvant chemotherapy.

Authors:  Ruixiang Zhang; Ying Hu; Tao Zhou; Wenbo Han; Yang Liu; Juanjuan Qian; Yanhui Chen; Xianben Liu; Shilei Liu; Yongkui Yu; Hui Zeng; Henghui Zhang; Yin Li
Journal:  J Thorac Dis       Date:  2020-08       Impact factor: 2.895

2.  Dose escalation of 3D radiotherapy is effective for esophageal squamous cell carcinoma: a multicenter retrospective analysis (3JECROG R-03).

Authors:  Wencheng Zhang; Jingjing Zhao; Weiming Han; Hualei Zhang; Xin Wang; Chen Li; Junqiang Chen; Xiaomin Wang; Yidian Zhao; Xueying Qiao; Zhiguo Zhou; Chun Han; Shuchai Zhu; Wenbin Shen; Lan Wang; Xiaolin Ge; Xinchen Sun; Kaixian Zhang; Miaomiao Hu; Ling Li; Chongli Hao; Gaofeng Li; Yonggang Xu; Yadi Wang; Na Lu; Miaoling Liu; Shuai Qian; Zefen Xiao; Ping Wang; Qingsong Pang
Journal:  Ann Transl Med       Date:  2020-09

3.  Carbon Ion Therapy Inhibits Esophageal Squamous Cell Carcinoma Metastasis by Upregulating STAT3 Through the JAK2/STAT3 Signaling Pathway.

Authors:  Hongtao Luo; Zhen Yang; Qiuning Zhang; Lihua Shao; Shihong Wei; Ruifeng Liu; Zheng Li; Yichao Geng; Chengcheng Li; Xiaohu Wang
Journal:  Front Public Health       Date:  2020-11-20

4.  Melatonin sensitizes esophageal cancer cells to 5‑fluorouracil via promotion of apoptosis by regulating EZH2 expression.

Authors:  Mengti Zhang; Mengli Zhang; Ruijia Li; Rui Zhang; Yueli Zhang
Journal:  Oncol Rep       Date:  2021-03-02       Impact factor: 3.906

5.  Comparison of a modified one-piece mechanical and double-layer hand-sewn anastomosis in McKeown esophagogastrectomy: A single-institute retrospective study.

Authors:  Kunshou Zhu; Jiulong Zhang; Xiaohui Chen; Yujie Deng; Shaofeng Lin; Yibin Cai; Guibin Weng
Journal:  Mol Clin Oncol       Date:  2021-05-12

6.  Biological dosiomic features for the prediction of radiation pneumonitis in esophageal cancer patients.

Authors:  Chanon Puttanawarut; Nat Sirirutbunkajorn; Suphalak Khachonkham; Poompis Pattaranutaporn; Yodchanan Wongsawat
Journal:  Radiat Oncol       Date:  2021-11-14       Impact factor: 3.481

7.  Single-Agent Versus Double-Agent Chemotherapy in Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma: Prospective, Randomized, Multicenter Phase II Clinical Trial.

Authors:  Zhenhuan Zhao; Yixue Wen; Dongbiao Liao; Jidong Miao; Yan Gui; Hongwei Cai; Yang Chen; Min Wei; Qiang Jia; Honggang Tian; Mingqiang Sun; Yu Zhang; Gang Feng; Xiaobo Du
Journal:  Oncologist       Date:  2020-09-28

8.  Application of next-generation sequencing in resistance genes of neoadjuvant chemotherapy for esophageal cancer.

Authors:  Jizhao Liu; Wenqun Xing; Qingnan Tian; Yin Li; Xianben Liu; Haibo Sun; Kun Gao; Xiankai Chen; Yan Zheng
Journal:  Transl Cancer Res       Date:  2020-08       Impact factor: 1.241

Review 9.  Primary small cell carcinoma of the esophagus: progression in the last decade.

Authors:  Anqi Ji; Runsen Jin; Renquan Zhang; Hecheng Li
Journal:  Ann Transl Med       Date:  2020-04

10.  Small nucleolar RNA host gene 22 (SNHG22) promotes the progression of esophageal squamous cell carcinoma by miR-429/SESN3 axis.

Authors:  Zhong-Wen Li; Ting-You Zhang; Guo-Jun Yue; Xin Tian; Jin-Zhi Wu; Guang-Yong Feng; Yong-Sheng Wang
Journal:  Ann Transl Med       Date:  2020-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.